Immupharma PLC Initiation of Research

TIDMIMM

Immupharma PLC

11 July 2022

RNS REACH 11 July 2022

ImmuPharma PLC

("ImmuPharma" or the "Company")

INITIATION OF RESEARCH

ImmuPharma PLC (LSE:IMM), the specialist drug discovery and development company, notes that its joint broker, Stanford Capital Partners ("SCP") has today initiated research coverage on the Company.

The full text of the report can be accessed via SCP's website: www.stanfordcp.co.uk/research/ and via Research Tree. Investors are required to self-certify and register in order to access the equity research.

 
 For further information please contact: ImmuPharma PLC ( www.immupharma.com ) 
    Tim McCarthy, Chairman and Chief Executive 
    Officer                                       +44 (0) 207 206 2650 
   Lisa Baderoon, Head of Investor Relations 
    & Non-Executive Director                      + 44 (0) 7721 413496 
   SPARK Advisory Partners Limited (NOMAD) 
    Neil Baldwin                                  +44 (0) 203 36 8 3550 
 
    Stanford Capital Partners (Joint Broker) 
    Patrick Claridge, John Howes, Bob Pountney     +44 (0) 20 3650 3650 
 
    SI Capital (Joint Broker) 
    Nick Emerson                                   +44 (0) 1483 413500

Notes to Editors

About ImmuPharma PLC

ImmuPharma PLC (LSE AIM: IMM) is a specialty biopharmaceutical company that discovers and develops peptide-based therapeutics. The Company's portfolio includes novel peptide therapeutics for autoimmune diseases and anti-infectives. The lead program, Lupuzor(TM), is a first-in class autophagy immunomodulator for the treatment of Lupus and preclinical analysis suggest therapeutic activity for many other autoimmune diseases that share the same autophagy mechanism of action.

The new international Phase 3 trial for Lupuzor(TM) is being funded by Avion, who have the exclusive rights to commercialise Lupuzor(TM) in the US. The rest of the world rights remain with ImmuPharma and partnering discussions will be an integral part of creating further opportunities for Lupuzor(TM) in Lupus and the P140 platform across several additional indication targets going forward. The next indication being Chronic inflammatory demyelinating polyneuropathy (CIDP)

For additional information about ImmuPharma please visit www.immupharma.co.uk

ImmuPharma's LEI (Legal Entity Identifier) code: 213800VZKGHXC7VUS895.

About Reach announcements

Reach is an investor communication service aimed at assisting listed and unlisted (including AIM quoted) companies to distribute media only / non-regulatory news releases such as marketing messages, corporate and product information into the public domain. An RNS Regulatory announcement is required to be notified under the AIM Rules for Companies.

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

Reach is a non-regulatory news service. By using this service an issuer is confirming that the information contained within this announcement is of a non-regulatory nature. Reach announcements are identified with an orange label and the word "Reach" in the source column of the News Explorer pages of London Stock Exchange's website so that they are distinguished from the RNS UK regulatory service. Other vendors subscribing for Reach press releases may use a different method to distinguish Reach announcements from UK regulatory news.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

NRAGUGDRUXBDGDB

(END) Dow Jones Newswires

July 11, 2022 02:00 ET (06:00 GMT)

Immupharma (LSE:IMM)
Historical Stock Chart
From Jul 2024 to Aug 2024